Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing
PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles , an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.
- PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles , an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.
- In contrast, traditional assays require the difficult preparation of live influenza virus, potentially expose researchers to infection, and need dedicated containment facilities for pandemic virus strains.
- TiterSafe particles mimic the architecture of live virus, featuring surface influenza proteins hemagglutinin (HA) and neuraminidase (NA) along with an interior protein core.
- Inhibition of this clumping by anti-HA antibodies in serum (an "HAI assay") is the standard FDA-accepted method for influenza vaccine assessment.